Differentiating Plovamer Acetate and Glatiramer Acetate: Efficacy and Mechanism of Action in a Preclinical Model of Multiple Sclerosis (P1.187)
Citation Manager Formats
Make Comment
See Comments

Abstract
OBJECTIVE: To compare the response to plovamer acetate (PA) and glatiramer acetate (GA) and investigate the mechanism of action (MOA) in a preclinical model of relapsing-remitting multiple sclerosis (RRMS). BACKGROUND: PA is a copolymer mixture of four amino acids of defined ratio, rationally designed to have improved efficacy over GA. PA competitively binds to MHC II with higher affinity than GA and drives a T-helper cell (Th)2-like response. PA is undergoing Phase II testing for RRMS. METHODS: Experimental autoimmune encephalomyelitis (EAE) was induced in SJL/J mice. PA, GA or vehicle were administered subcutaneously either daily or three times/week, or were co-administered with PLP at EAE induction. Disease severity was measured using a standard 0-5 clinical score (CS) scale. Blood and plasma were collected weekly for hematology and cytokine production measurements, respectively. Mouse splenocytes were cultured and re-stimulated to assess proliferation and cytokine production. RESULTS: Disease onset was delayed significantly vs. vehicle with daily PA (5 days; p<0.001), daily GA (2 days; p<0.01), PA 3x/week (6 days; p<0.001), but not GA 3x/week. In addition, PA dose-dependently decreased EAE severity when co-administered at disease induction: 10 or 30 mg/kg completely abolished disease and 3 mg/kg resulted in a 60% decrease in EAE severity. In contrast, co-administration of 3 or 10 mg/kg of GA was not efficacious; 30 mg/kg resulted in a similar decrease in CS as seen with 3 mg/kg PA, suggesting that PA was 10x more potent than GA in this preclinical model. Additional results supported previous findings that PA induces a Th2 shift. CONCLUSIONS: When compared with GA, PA more potently delays disease onset and reduces disease severity, as demonstrated in a preclinical model of RRMS. Continuing studies will provide further details on MOA. Study Supported by: Merck Serono SA Geneva, Switzerland, a subsidiary of Merck KGaA, Darmstadt, Germany.
Disclosure: Dr. Savinainen has received personal compensation for activities with EMD Serono. Dr. Crook has received personal compensation for activities with EMD Serono as an employee. Dr. Crandall has received personal compensation for activities with EMD Serono as an employee. Dr. Seng has received personal compensation for activities with EMD Serono as an employee. Dr. Boschert has received personal compensation for activities with EMD Serono as an employee. Dr. Dellovade has received personal compensation for activities with EMD Serono as an employee.
Monday, April 28 2014, 3:00 pm-6:30 pm
- Copyright © 2014 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.